Traboulsee, Anthony et al "Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004)." Neurology 86.16 Supplement (2016): PL02.004. Web. 06 Feb. 2023.